These results suggest that the molecular disease mechanism for the CPVT-causing CaM mutations is dysregulation of cardiac SR Ca2+ release, in line with CPVT-causing mutations in RyR2. This evidence concerns the gene RYR2 and catecholaminergic polymorphic ventricular tachycardia.